Hereditary Transthyretin Amyloidosis Market Expansion Continues, with Forecast Valuation of $2.09 Billion by 2029

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Hereditary Transthyretin Amyloidosis Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
Market valuation for hereditary transthyretin amyloidosis has seen robust expansion lately, projected to escalate from $1.36 billion in 2024 to $1.49 billion the subsequent year, achieving a compound annual growth rate of 9.3%. This upward trajectory during the preceding period is largely attributable to several factors, including the escalating frequency of the condition, heightened investment in research and development endeavors, a greater prevalence of cardiac amyloidosis diagnoses, heightened public and professional understanding of the disease, and ongoing improvement of global healthcare systems.

Hereditary Transthyretin Amyloidosis Market Size Forecast: What's the Projected Valuation by 2029?
Projections indicate a robust expansion for the hereditary transthyretin amyloidosis market, anticipating it to reach a valuation of $2.09 billion by 2029, fueled by a compound annual growth rate of 9.0% throughout the forecast window, which is underpinned by several key factors such as the increasing numbers of elderly individuals, escalating personal wealth, a higher prevalence of hereditary transthyretin amyloidosis diagnoses, increased investment in novel pharmaceutical agents, and a greater uptake of genetic screening procedures, while the period ahead is set to be characterized by significant trends including the introduction of sophisticated therapeutic offerings, progress in diagnostic methodologies, forward movement in pharmaceutical research, a strong need for potent treatments, and continuous evolution in medical instrumentation.

View the full report here:
https://www.thebusinessresearchcompany.com/report/hereditary-transthyretin-amyloidosis-global-market-report

What Are the Drivers Transforming the Hereditary Transthyretin Amyloidosis Market?
Anticipated expansion within the market for hereditary transthyretin amyloidosis is projected to be fueled by the steadily increasing number of elderly people.This demographic, defined as those aged 65 and above, frequently necessitates dedicated medical attention and assistance owing to the effects of aging.The rise in this older cohort stems from extended lifespans resulting from improvements in both medical science and general living standards.Hereditary transthyretin amyloidosis (hATTR) represents a substantial health concern for seniors, as it induces worsening nerve issues and heart muscle disease, thereby elevating the rate of illness among older adults.To illustrate, data from the Population Reference Bureau, a non-profit organization based in the US, indicated in January 2024 that the American populace at 65 years of age and over is slated to rise from 58 million in 2022 to 82 million by the year 2050, which signifies a 47 percent climb.Consequently, the expanding base of the elderly population serves as a primary catalyst pushing the hereditary transthyretin amyloidosis market forward.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=22003&type=smp

What Long-Term Trends Will Define the Future of the Hereditary Transthyretin Amyloidosis Market?
Key players within the hereditary transthyretin amyloidosis sector are focusing efforts on creating novel treatments, notably RNA interference (RNAi) therapies, aimed at diminishing the output of the transthyretin (TTR) protein. These RNAi agents function by employing RNA interference mechanisms to deactivate particular genes, which consequently lowers the synthesis of proteins responsible for the ailment. As an illustration of this groundbreaking development, Alnylam Pharmaceuticals, Incorporated, a company situated in the United States specializing in biopharmaceuticals, put forward a supplemental new drug application (sNDA) to the US Food and Drug Administration (FDA) in October 2024. This application sought approval for Vutrisiran (AMVUTTRA) to address transthyretin amyloidosis complicated by cardiomyopathy, emphasizing its advanced RNAi methodology engineered to suppress the troublesome TTR protein that drives the illness. Offering a subcutaneous route, Vutrisiran presents an administration schedule perceived as more accessible and user-friendly for patients when contrasted with established intravenous infusion methods, suggesting it could become a genuinely game-changing therapy for those afflicted with this severe disorder.

Which Segments in the Hereditary Transthyretin Amyloidosis Market Offer the Most Profit Potential?
The hereditary transthyretin amyloidosismarket covered in this report is segmented -

1) By Type: Oral; Subcutaneous Injection; Other Types
2) By Drug Class: RNAi Agents (Patisiran); Small Interfering RNAs (siRNAs) (Vutrisiran)
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies
4) By Application: Hospital; Clinic; Other Applications

Subsegments:

1) By Oral: Tafamidis; Diflunisal; Experimental Oral Therapies
2) By Subcutaneous Injection: Patisiran; Inotersen; Vutrisiran
3) By Other Types: Intravenous Therapies; Gene Silencing Therapies; CRISPR-Based Therapies

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=22003&type=smp

Which Firms Dominate the Hereditary Transthyretin Amyloidosis Market by Market Share and Revenue in 2025?
Major companies operating in the hereditary transthyretin amyloidosis market are Pfizer Inc., AbbVie Inc., Sanofi S.A., AstraZeneca plc, Novo Nordisk, Regeneron Pharmaceuticals Inc., Alexion Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., BridgeBio Pharma Inc., Akcea Therapeutics, Prothena Corporation plc, Intellia Therapeutics Inc., YoITech Therapeutics, Corino Therapeutics Inc., Attralus Inc., BSIM Therapeutics SA, Eidos Therapeutics, Autotac Bio Inc.

Which Regions Offer the Highest Growth Potential in the Hereditary Transthyretin Amyloidosis Market?
North America was the largest region in the hereditary transthyretin amyloidosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary transthyretin amyloidosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22003

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.